Endomysial antibodies or anti‐tissue transglutaminase type 2 IgA antibodies as a confirmatory test in children with celiac disease
Journal of Pediatric Gastroenterology and Nutrition · 2025
DOI: 10.1002/jpn3.12383 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2025. Verfasst von Amir Ben-Tov und 7 weiteren Autor:innen. Beteiligte Einrichtung: Maccabi Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Celiac Disease, Transglutaminases, Protein Glutamine gamma Glutamyltransferase 2, GTP-Binding Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: None.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
The no‐biopsy approach to diagnose celiac disease (CD), introduced in the 2012 European Society for Gastroenterology and Hepatology and Nutrition guidelines, requires an anti‐endomysial antibody (EMA) confirmatory serology test following a high‐positive immunoglobulin A anti‐tissue transglutaminase‐2 (anti‐TG2) antibody ≥10 times the upper limit of normal (ULN). The aim of this retrospective study is to compare EMA positivity and high‐positive anti‐TG2 in patients who had their confirmatory test within 2 months of their first high‐positive anti‐TG2 test. Among 933 patients who had high‐positive anti‐TG2 serology more than 10 times the ULN in their first sample, all had both high‐positive anti‐TG2 and positive EMA, most of them with very high EMA titers (99.6%) in their confirmatory test. In conclusion, we suggest that a repeated anti‐TG2 test can replace the EMA test as the confirmatory serology test for the confirmation of the diagnosis of CD in the no‐biopsy approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Maccabi Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel.
- Tel-Aviv Sourasky Medical Center, Dana-Dwek Children's Hospital, Pediatric Gastroenterology Institute, Tel Aviv, Israel.
- School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel Aviv, Israel.
- Schneider Children's Medical Center, Institute of Pediatric Gastroenterology, Nutrition, and Liver Diseases, Petah Tikva, Israel.
- Immunology Unit, National Laboratory, Maccabi Healthcare Services, Rechovot, Israel.
ORCID-Profile: Amir Ben-Tov
Förderung
- None
Zitieren
APA
Ben-Tov, A., Achler, T., Fayngor, R., Shamir, R., Supino, L., Weintraub, Y., Yerushalmy-Feler, A., & Cohen, S. (2025). Endomysial antibodies or anti‐tissue transglutaminase type 2 IgA antibodies as a confirmatory test in children with celiac disease. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.12383
Vancouver
Ben-Tov A, Achler T, Fayngor R, Shamir R, Supino L, Weintraub Y, et al. Endomysial antibodies or anti‐tissue transglutaminase type 2 IgA antibodies as a confirmatory test in children with celiac disease. Journal of Pediatric Gastroenterology and Nutrition. 2025. doi:10.1002/jpn3.12383
BibTeX
@article{BenTov2025,
author = {Ben-Tov, Amir and Achler, Tomer and Fayngor, Rochelle and Shamir, Raanan and Supino, Lia and Weintraub, Yael and Yerushalmy-Feler, Anat and Cohen, Shlomi},
title = {Endomysial antibodies or anti‐tissue transglutaminase type 2 IgA antibodies as a confirmatory test in children with celiac disease},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2025},
doi = {10.1002/jpn3.12383}
}
EUVIMED